BRPI0717976A2 - Composto ou um sal farmaceuticamente aceitável do mesmo, composição, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo - Google Patents

Composto ou um sal farmaceuticamente aceitável do mesmo, composição, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo Download PDF

Info

Publication number
BRPI0717976A2
BRPI0717976A2 BRPI0717976-6A BRPI0717976A BRPI0717976A2 BR PI0717976 A2 BRPI0717976 A2 BR PI0717976A2 BR PI0717976 A BRPI0717976 A BR PI0717976A BR PI0717976 A2 BRPI0717976 A2 BR PI0717976A2
Authority
BR
Brazil
Prior art keywords
alkyl
substituted
group
unsubstituted
phenyl
Prior art date
Application number
BRPI0717976-6A
Other languages
English (en)
Portuguese (pt)
Inventor
David Chen
Christopher L Franklin
Peter R Guzzo
Lins S Lin
Michael M-C Lo
Ravi P Nargund
Iyassu K Sebhat
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0717976A2 publication Critical patent/BRPI0717976A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0717976-6A 2006-10-20 2007-10-16 Composto ou um sal farmaceuticamente aceitável do mesmo, composição, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo BRPI0717976A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85319306P 2006-10-20 2006-10-20
US60/853193 2006-10-20
PCT/US2007/022087 WO2008051406A2 (en) 2006-10-20 2007-10-16 Substituted imidazoles as bombesin receptor subtype-3 modulators

Publications (1)

Publication Number Publication Date
BRPI0717976A2 true BRPI0717976A2 (pt) 2013-11-12

Family

ID=39325111

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717976-6A BRPI0717976A2 (pt) 2006-10-20 2007-10-16 Composto ou um sal farmaceuticamente aceitável do mesmo, composição, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo

Country Status (13)

Country Link
US (1) US8193228B2 (enExample)
EP (1) EP2091937A2 (enExample)
JP (1) JP5047299B2 (enExample)
KR (1) KR20090064458A (enExample)
CN (1) CN101528730A (enExample)
AU (1) AU2007309570B2 (enExample)
BR (1) BRPI0717976A2 (enExample)
CA (1) CA2666310C (enExample)
IL (1) IL198004A0 (enExample)
MX (1) MX2009004112A (enExample)
NO (1) NO20091957L (enExample)
RU (1) RU2009118935A (enExample)
WO (1) WO2008051406A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083623A1 (en) 2006-10-20 2009-08-05 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
US8106070B2 (en) 2006-10-20 2012-01-31 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
WO2009123164A1 (ja) * 2008-04-02 2009-10-08 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するヘテロ環誘導体
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013135674A1 (en) * 2012-03-12 2013-09-19 Syngenta Participations Ag Insecticidal 2-aryl-acetamide compounds
CN103497159B (zh) * 2013-09-18 2015-08-12 苏州岚云医药科技有限公司 1,2-二取代-5-磺酰基咪唑类化合物的制备方法
MX389001B (es) 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
WO2020086816A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
AU2020376950B2 (en) 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962117A (en) 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
JPH07243068A (ja) 1994-03-08 1995-09-19 Murata:Kk 金属表面の電解処理方法
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
CA2275796A1 (en) 1996-12-23 1998-07-02 Donald Joseph Phillip Pinto Nitrogen containing heteroaromatics as factor xa inhibitors
JPH11217348A (ja) 1997-10-15 1999-08-10 Otsuka Pharmaceut Co Ltd フルオレノン誘導体の製造法
CA2314401A1 (en) 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
AR024077A1 (es) 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
JP3842976B2 (ja) 2000-03-17 2006-11-08 富士通株式会社 分布帰還型半導体レーザとその製造方法
JP4790969B2 (ja) 2000-08-11 2011-10-12 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
WO2002098840A1 (en) 2001-06-04 2002-12-12 Eisai Co., Ltd. Carboxylic acid derivative and medicine comprising salt or ester of the same
WO2003016291A1 (en) 2001-08-10 2003-02-27 Nippon Chemiphar Co., Ltd. ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2003321455A (ja) 2002-02-28 2003-11-11 Nissan Chem Ind Ltd ｏ−置換ベンゾイル化合物及びこれを有効成分とする除草剤
DE10224844A1 (de) 2002-06-05 2004-01-08 Solvay Pharmaceuticals Gmbh Nicht-peptidische BRS-3-Agonisten
AU2003281039A1 (en) 2002-07-10 2004-02-02 Sumitomo Pharmaceuticals Co., Ltd. Imidazole derivative
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
BR0314898A (pt) 2002-11-19 2005-08-02 Galderma Res & Dev Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
MXPA05005334A (es) 2002-11-25 2005-11-17 Galderma Res & Dev Compuestos bifenilo activadores de los receptores de tipo receptores activados de la proliferacion de peroxisoma gamma y su uso en composiciones cosmeticas o farmaceuticas.
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
AU2004210711B2 (en) * 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
WO2005035551A2 (en) 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
BR0318625A (pt) 2003-12-04 2006-10-31 Wyeth Corp biaril sulfonamidas e métodos para usar as mesmas
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2005080346A1 (en) * 2004-02-12 2005-09-01 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
GB0403578D0 (en) 2004-02-18 2004-03-24 Biofocus Discovery Ltd Compounds which interact with the G-protein coupled receptor family
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US8106070B2 (en) * 2006-10-20 2012-01-31 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
EP2083623A1 (en) 2006-10-20 2009-08-05 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators

Also Published As

Publication number Publication date
AU2007309570A1 (en) 2008-05-02
JP5047299B2 (ja) 2012-10-10
WO2008051406A3 (en) 2008-07-24
EP2091937A2 (en) 2009-08-26
RU2009118935A (ru) 2010-11-27
NO20091957L (no) 2009-07-17
MX2009004112A (es) 2009-05-11
CA2666310C (en) 2012-07-31
KR20090064458A (ko) 2009-06-18
WO2008051406A2 (en) 2008-05-02
JP2010506919A (ja) 2010-03-04
US20100022598A1 (en) 2010-01-28
US8193228B2 (en) 2012-06-05
AU2007309570B2 (en) 2012-07-12
CA2666310A1 (en) 2008-05-02
IL198004A0 (en) 2009-12-24
CN101528730A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
US8193228B2 (en) Substituted imidazole as bombesin receptor subtype-3 modulators
JP5319550B2 (ja) 置換スピロクロマノン誘導体
BRPI0709972A2 (pt) composto, composição farmacêutica, e, uso de um composto
EP2043634A2 (en) Substituted pyrazoles as ghrelin receptor antagonists
AU2007332867B2 (en) Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
WO2007041052A2 (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US8410284B2 (en) Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2007120688A2 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
US8183275B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
US8318767B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
AU2006320797A1 (en) Heterocycle-substituted 3-alkyl azetidine derivatives

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]